Poolbeg Pharma is very pleased to see the approval of multiple CAR T cell therapies for earlier treatment of multiple myeloma. As an oral preventative therapy for CRS, POLB 001 has the potential to enable broader, safer delivery of cancer immunotherapies to cancer patients.
The FDA has approved two CAR-T cell therapies for the earlier treatment of multiple myeloma. The first approval, for Bristol Myers Squibb and 2seventy Bio’s Abecma, came Thursday, followed by that of Johnson & Johnson and Legend Biotech’s Carvykti on Friday.
The approvals come three weeks after an FDA advisory committee unanimously recommended Carvykti as a second-line treatment for patients with refractory multiple myeloma, and backed Abecma by a vote of 8-3 for patients who had received at least two previous drug regimens. Carvykti joins seven other therapies that can be used as second-line treatments for multiple myeloma if initial therapies fail.
Both Abecma and Carvykti reprogram a patient’s T-cells to eliminate cells that express B-cell maturation antigen (BCMA), which is present in normal B-cells but overexpressed in multiple myeloma.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
